BCL2 and cancer: Previous studies have shown that inhibition of BCL-2 and CDK4/6 combined with endocrine therapy can inhibit proliferation and induce apoptosis of cancer cells, including phenotype senescent cells, thereby enhancing reactivity in vivo (10).